Full Name
Dr. Jordan Gauthier MD, MSc
Job Title
Associate Professor
Company/Affiliation
Fred Hutchinson Cancer Research Center
Speaker Bio
Jordan Gauthier, MD, MSc, is an Associate Professor in the Clinical Research Division at the Fred Hutchinson Cancer Center and in the Division of Hematology and Oncology at the University of Washington in Seattle. He is a hematologist-oncologist with specialized expertise in immune effector-cell (IEC) therapies, including CAR T-cell therapies and bispecific antibodies, with a particular focus on chronic lymphocytic leukemia (CLL) and other lymphoid malignancies.
Dr. Gauthier completed his medical training and hematology fellowship in France at Lille University Hospital, where he subsequently joined the faculty in the Bone Marrow Transplantation and Immunotherapy Program. In 2017, he moved to Seattle as an Immunotherapy Clinical Research Fellow at Fred Hutch, where he was the inaugural recipient of the Immunotherapy Integrated Research Center Fellowship Award and conducted translational research in the laboratory of Dr. Cameron Turtle, whose pioneering work led to the development and FDA approval of the CD19 CAR T-cell therapy lisocabtagene maraleucel. Dr. Gauthier joined the faculty at Fred Hutch and the University of Washington in 2019 and was promoted to Associate Professor in 2023.
Dr. Gauthier leads a comprehensive clinical and translational research program aimed at improving the efficacy and safety of immune effector-cell therapies for patients with high-risk and refractory lymphoid and plasma cell malignancies, including CLL. He is the principal investigator of multiple early- and late-phase clinical trials, including several investigator-initiated studies, and has established one of the largest academic biorepositories of biospecimens from patients treated with CAR T-cell therapy. He also serves as Medical Director of the Fred Hutch Immunotherapy Long-Term Follow-Up Program for patients receiving IEC therapies.
Dr. Gauthier has authored 98 peer-reviewed publications, including 37 as first or senior author, in journals such as Blood, Blood Advances, Haematologica, and Nature Reviews Clinical Oncology, and has delivered more than 40 invited lectures internationally. His work has helped define predictors of response, resistance, and toxicity following CAR T-cell therapy and informs the rational integration of CAR T-cell therapies and bispecific antibodies in CLL. Specifically, he was the first to report the feasibility, safety, and efficacy of combining the BTK inhibitor ibrutinib with CD19 CAR T cells in patients with refractory CLL.
Today, Dr. Gauthier will discuss the evolving role of immune effector-cell therapies in CLL, highlighting clinical outcomes, toxicity management, and emerging strategies to optimize safety and durability of response.
Dr. Gauthier completed his medical training and hematology fellowship in France at Lille University Hospital, where he subsequently joined the faculty in the Bone Marrow Transplantation and Immunotherapy Program. In 2017, he moved to Seattle as an Immunotherapy Clinical Research Fellow at Fred Hutch, where he was the inaugural recipient of the Immunotherapy Integrated Research Center Fellowship Award and conducted translational research in the laboratory of Dr. Cameron Turtle, whose pioneering work led to the development and FDA approval of the CD19 CAR T-cell therapy lisocabtagene maraleucel. Dr. Gauthier joined the faculty at Fred Hutch and the University of Washington in 2019 and was promoted to Associate Professor in 2023.
Dr. Gauthier leads a comprehensive clinical and translational research program aimed at improving the efficacy and safety of immune effector-cell therapies for patients with high-risk and refractory lymphoid and plasma cell malignancies, including CLL. He is the principal investigator of multiple early- and late-phase clinical trials, including several investigator-initiated studies, and has established one of the largest academic biorepositories of biospecimens from patients treated with CAR T-cell therapy. He also serves as Medical Director of the Fred Hutch Immunotherapy Long-Term Follow-Up Program for patients receiving IEC therapies.
Dr. Gauthier has authored 98 peer-reviewed publications, including 37 as first or senior author, in journals such as Blood, Blood Advances, Haematologica, and Nature Reviews Clinical Oncology, and has delivered more than 40 invited lectures internationally. His work has helped define predictors of response, resistance, and toxicity following CAR T-cell therapy and informs the rational integration of CAR T-cell therapies and bispecific antibodies in CLL. Specifically, he was the first to report the feasibility, safety, and efficacy of combining the BTK inhibitor ibrutinib with CD19 CAR T cells in patients with refractory CLL.
Today, Dr. Gauthier will discuss the evolving role of immune effector-cell therapies in CLL, highlighting clinical outcomes, toxicity management, and emerging strategies to optimize safety and durability of response.
Speaking At
